longevityharbor

Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· longevityutaAudio language not provided

Apitegromab, myostatin and lean mass: what the video description covers

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →
#hallmarksDiscuss this topic

At a glance

Automatic summary · not editorially reviewed

The description says apitegromab, a monoclonal antibody that inhibits myostatin activation, is approved in the US for a defined spinal muscular atrophy group; in the EMBRAZE phase-2 trial with tirzepatide in adults with overweight or obesity, lean mass loss after 24 weeks was smaller with apitegromab than with tirzepatide plus placebo. [1]

  1. The description says apitegromab, a monoclonal antibody that inhibits myostatin activation, was approved in the US in September 2026 for a defined spinal muscular atrophy group. [1]

  2. In EMBRAZE, after 24 weeks, fat-free mass loss was smaller with apitegromab than with tirzepatide plus placebo in adults with overweight or obesity. [1]

  3. The description says apitegromab is not approved for age-related muscle loss or as a companion therapy to tirzepatide for weight reduction. [1]

Myostatin brake and apitegromab's US approval

The description states that the body has a natural muscle brake: myostatin limits skeletal muscle growth. Apitegromab is described as a monoclonal antibody that inhibits myostatin activation. According to the description, it was approved in the US in September 2026 under the name ISEMBYLD for a clearly defined patient group with spinal muscular atrophy. The description also says there is currently no EU approval for ISEMBYLD/apitegromab and that a marketing authorisation application was withdrawn. It stresses that apitegromab is not approved as a general muscle-building agent, for age-related muscle loss or as a companion therapy to tirzepatide for weight reduction. [1]

EMBRAZE: lean mass with apitegromab plus tirzepatide

The description reports that the randomised phase-2 trial EMBRAZE tested apitegromab together with tirzepatide in adults with overweight or obesity. After 24 weeks, the loss of fat-free mass was smaller in the apitegromab group than in the group receiving tirzepatide plus placebo. The description cautions that lean mass is not automatically the same as pure skeletal muscle mass. It also notes that the trial is research and that interesting findings are not proof of a longevity effect. [1]

SAPPHIRE and open questions in the description

The description lists the SAPPHIRE study in spinal muscular atrophy among the topics covered, citing a phase-3, double-blind, randomised, placebo-controlled trial in nonambulatory type 2 or type 3 spinal muscular atrophy. It also promises to address risks and open questions and to explain why targeting myostatin could one day matter for preserving muscle mass with ageing. The description does not report SAPPHIRE results or name specific risks; it states that the video provides independent scientific information and is not advertising, a recommendation for a drug or individual medical advice. [1]

Context & limits

This is based only on the video description; the video and transcript were not reviewed. The description does not report SAPPHIRE results or specific risks, and it does not establish a longevity effect.

Based on the creator’s description; the full video and transcript were not analyzed.

#Myostatin#Apitegromab#LeanMass#SpinalMuscularAtrophy
[1] Forscher blockieren die „Muskelbremse“ – was das neue Medikament wirklich kann
Quoted passages in the original language
hemmt die Aktivierung von Myostatin
Verlust an fettfreier Masse in der Apitegromab-Gruppe
nicht als allgemeines Mittel zum Muskelaufbau

About this video

Creator description · original textText language: German

Unser Körper besitzt tatsächlich eine Art natürliche „Muskelbremse“: Myostatin begrenzt das Wachstum der Skelettmuskulatur. Genau hier setzt Apitegromab an. Der monoklonale Antikörper hemmt die Aktivierung von Myostatin und wurde im September 2026 in den USA unter dem Namen ISEMBYLD für eine klar definierte Patientengruppe mit spinaler Muskelatrophie (SMA) zugelassen. Spannend für die Healthy-Aging-Forschung ist aber noch etwas anderes: In der randomisierten Phase-2-Studie EMBRAZE wurde Apitegromab gemeinsam mit Tirzepatid bei Erwachsenen mit Übergewicht oder Adipositas untersucht. Nach 24 Wochen war der Verlust an fettfreier Masse in der Apitegromab-Gruppe geringer als unter Tirzepatid plus Placebo. Was bedeutet das wirklich? Und könnte die gezielte Beeinflussung von Myostatin irgendwann auch für den Erhalt von Muskelmasse beim Älterwerden relevant werden? In diesem Video ordne ich ein: • was Myostatin in unserem Körper macht • wie Apitegromab in diesen Signalweg eingreift • wofür der Wirkstoff in den USA tatsächlich zugelassen wurde • was die SAPPHIRE-Studie bei spinaler Muskelatrophie gezeigt hat • was die EMBRAZE-Studie zu Tirzepatid und fettfreier Masse gezeigt hat • warum „Lean Mass“ nicht automatisch mit reiner Skelettmuskelmasse gleichzusetzen ist • welche Risiken und offenen Fragen bestehen • und warum interessante Forschung noch kein Beweis für einen Longevity-Effekt ist Wichtig: Apitegromab ist nicht als allgemeines Mittel zum Muskelaufbau, zur Behandlung altersbedingten Muskelverlusts oder als Begleittherapie zu Tirzepatid zur Gewichtsreduktion zugelassen. Für diese Fragestellungen handelt es sich um Forschung. In der EU besteht derzeit keine Zulassung für ISEMBYLD/Apitegromab. 🔬 Quellen / weiterführende Literatur: U.S. Food and Drug Administration (FDA), 11.09.2026: FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy. FDA Prescribing Information: ISEMBYLD (apitegromab-mstn), US Prescribing Information, 2026. Crawford TO et al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2025;24(9):727–739. doi: 10.1016/S1474-4422(25)00225-X Pratley RE et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. 2026;32:2673–2678. doi: 10.1038/s41591-026-04440-4 ClinicalTrials.gov: NCT06445075 European Medicines Agency (EMA): Isembyld (apitegromab) – Withdrawal of the marketing authorisation application, 13.08.2026. ⚠️ Hinweis: Dieses Video dient der unabhängigen wissenschaftlichen Information und Einordnung aktueller Forschung. Es stellt keine Werbung oder Empfehlung für ein Arzneimittel und keine individuelle medizinische Beratung dar. Besprochene Forschungsanwendungen sind nicht mit einer arzneimittelrechtlichen Zulassung gleichzusetzen. Zulassungsstatus, Studienergebnisse und deren Grenzen werden im Video ausdrücklich eingeordnet. #Myostatin #Muskelmasse #HealthyAging #Longevity #Apitegromab

longevityuta · 7 min · Source published: 2026-09-27

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…